Targeting OST Redundancy to Treat Osteosarcoma
Official title: Targeting Oligosaccharyltransferse Redundancy for the Treatment of Osteosarcoma
Funded at Rutgers Biomedical and Health Sciences · NIH-11426739 · Data updated 2026-11-12
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | July 13, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $550,084 |
| NIH project number | 1R01CA315897-01 |
| Project ID | NIH-11426739 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with advanced osteosarcoma or related bone cancers who may benefit from future OST-targeted treatments.
✕Less likely to help
Patients without osteosarcoma or those whose cancer does not respond to OST-targeted strategies may not benefit.
What this research studies
This project focuses on osteosarcoma, a tough pediatric/adolescent cancer. Researchers will optimize small molecules that inhibit the oligosaccharyltransferase (OST) enzyme to selectively attack cancer cells while sparing normal cells. They will work on improving how long the drugs last in the body, how strong they are, how well they dissolve, and which OST subunit they target. The work combines cell-based experiments and animal models to identify lead drug candidates that could move toward early human testing.
Why it matters
Potential benefit: If successful, patients with osteosarcoma could receive more effective and tolerable targeted therapies.
How similar studies have gone: Preclinical data show OST inhibitors can halt tumor growth in cells and reduce tumors in animal models, suggesting potential but needs clinical confirmation.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Contessa, Joseph N — Rutgers Biomedical and Health Sciences
- Study coordinator: Contessa, Joseph N
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
-
Canine osteosarcoma immunity boost from hyperactivated dendritic cells
A study tests a way to spark a strong anti-tumor immune response in dogs with bone cancer using highly activated immune cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.